{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:44:33Z","timestamp":1757450673741,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"French Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ischemic heart attack is the leading cause of death worldwide. Ten percent of cases will die within an hour. Of the survivors, around 30% will have suffered a severe infarction which will lead to the irreparable destruction of 1 to 2 billion myocardial cells, causing an irreversible secondary heart failure with a poor prognosis in the short. The heart is a totally differentiated organ with a very low capacity for self-regeneration. No current treatment can prevent this fatal outcome, but only slow it down. For these reasons, cell therapy has generated enormous hope, but achieved somewhat disappointing results, depending on the type\/source of cells which were used. From the end of 2002, our group conducted a Pilot study using immuno-selected autologous peripheral-blood (PB) CD34<jats:sup>+<\/jats:sup> cells in a small cohort of patients who had experienced a heart attack with poor prognosis. Three of these patients were immediately considered for heart transplant but lacked a readily available donor. CD34<jats:sup>+<\/jats:sup> cells were trans-epicardially delivered at the end of a coronary artery by-pass graft (CABG) operation without reperfusing the ischemic area, which was performed on a compassionate basis. All but one patient showed a marked and sustained improvement in their cardiac function parameters from the baseline values, associated with both cardiac tissue repair and revascularization, as demonstrated by PetScan examination. The patients\u2019 outcomes have been recently updated. Six out of seven patients have survived in good enough conditions for at least 12\u00a0years after cell therapy, including those three initially recommended for heart transplant and who have avoided it. Presently, five out of seven patients are still alive with an average follow-up of 17\u00a0years (range 16\u201320\u00a0years), which is very unusual after CABG for patients with such a poor initially prognosis.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s12015-023-10643-w","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T08:01:58Z","timestamp":1697788918000},"page":"247-257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transforming Perspectives in Cardiac Cell Therapy: Hypothesis and Commentary Following Updated Results of a Pilot Study Investigating Very Long-Term Clinical Outcomes in Severe AMI Patients Following Trans-Epicardial Injection of Peripheral Blood CD34+ Cells"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-5994","authenticated-orcid":false,"given":"Philippe","family":"H\u00e9non","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dallemand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"issue":"9921","key":"10643_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(13)61752-3","volume":"383","author":"SS Mahmood","year":"2014","unstructured":"Mahmood, S. S., Levy, D., Vasan, R. S., & Wang, T. J. (2014). The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. Lancet (London, England), 383(9921), 999\u20131008. https:\/\/doi.org\/10.1016\/S0140-6736(13)61752-3","journal-title":"Lancet (London, England)"},{"key":"10643_CR2","first-page":"1","volume":"2021-12-7649","author":"B Engdhal","year":"2021","unstructured":"Engdhal, B., & Ziegel, B. (2021). Statistics on Myocardial Infarctions 2021. The Sweden National Board of Health and Welfare, 2021-12\u20137649, 1\u20134.","journal-title":"The Sweden National Board of Health and Welfare"},{"issue":"6","key":"10643_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2022.0662","volume":"7","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Leifheit, E. C., & Krumholz, H. M. (2022). Trends in 10-Year Outcomes Among Medicare Beneficiaries Who Survived an Acute Myocardial Infarction. JAMA cardiology, 7(6), 613\u2013622. https:\/\/doi.org\/10.1001\/jamacardio.2022.0662","journal-title":"JAMA cardiology"},{"key":"10643_CR4","unstructured":"WHO press release 12\/09\/2019."},{"issue":"7347","key":"10643_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nature10147","volume":"473","author":"MA Laflamme","year":"2011","unstructured":"Laflamme, M. A., & Murry, C. E. (2011). Heart regeneration. Nature, 473(7347), 326\u2013335. https:\/\/doi.org\/10.1038\/nature10147","journal-title":"Nature"},{"key":"10643_CR6","doi-asserted-by":"publisher","unstructured":"Pasquet, S., Sovalat, H., H\u00e9non, P., Bischoff, N., Arkam, Y., Ojeda-Uribe, M., \u2026 Monassier, J.-P. (2009). Long-term benefit of intracardiac delivery of autologous granulocyte\u2013colony-stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct. Cytotherapy, 11(8), 1002\u20131015. https:\/\/doi.org\/10.3109\/14653240903164963","DOI":"10.3109\/14653240903164963"},{"key":"10643_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jamacardio.2016.1465","volume":"1","author":"M Dal\u00e9n","year":"2016","unstructured":"Dal\u00e9n, M., Lund, L. H., Ivert, T., Holzmann, M. J., & Sartipy, U. (2016). Survival After Coronary Artery Bypass Grafting in Patients With Preoperative Heart Failure and Preserved vs Reduced Ejection Fraction. JAMA Cardiology, 1, 530\u2013538. https:\/\/doi.org\/10.1001\/jamacardio.2016.1465","journal-title":"JAMA Cardiology"},{"key":"10643_CR8","doi-asserted-by":"publisher","unstructured":"Menasch\u00e9, P., Alfieri, O., Janssens, S., McKenna, W., Reichenspurner, H., Trinquart, L., \u2026 Hag\u00e8ge, A. A. (2008). The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation, 117(9), 1189\u20131200. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.734103","DOI":"10.1161\/CIRCULATIONAHA.107.734103"},{"key":"10643_CR9","doi-asserted-by":"publisher","unstructured":"Perin, E. C., Willerson, J. T., Pepine, C. J., Henry, T. D., Ellis, S. G., Zhao, D. X. M., \u2026 Cardiovascular Cell Therapy Research Network (CCTRN). (2012). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA, 307(16), 1717\u20131726https:\/\/doi.org\/10.1001\/jama.2012.418","DOI":"10.1001\/jama.2012.418"},{"issue":"2","key":"10643_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/term.137","volume":"3","author":"EJ Molina","year":"2009","unstructured":"Molina, E. J., Palma, J., Gupta, D., Torres, D., Gaughan, J. P., Houser, S., & Macha, M. (2009). Reverse remodeling is associated with changes in extracellular matrix proteases and tissue inhibitors after mesenchymal stem cell (MSC) treatment of pressure overload hypertrophy. Journal of Tissue Engineering and Regenerative Medicine, 3(2), 85\u201391. https:\/\/doi.org\/10.1002\/term.137","journal-title":"Journal of Tissue Engineering and Regenerative Medicine"},{"key":"10643_CR11","doi-asserted-by":"publisher","unstructured":"Berry, M. F., Engler, A. J., Woo, Y. J., Pirolli, T. J., Bish, L. T., Jayasankar, V., \u2026 Sweeney, H. L. (2006). Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. American Journal of Physiology. Heart and Circulatory Physiology, 290(6), H2196\u20132203. https:\/\/doi.org\/10.1152\/ajpheart.01017.2005","DOI":"10.1152\/ajpheart.01017.2005"},{"key":"10643_CR12","doi-asserted-by":"publisher","unstructured":"Amado, L. C., Schuleri, K. H., Saliaris, A. P., Boyle, A. J., Helm, R., Oskouei, B., \u2026 Hare, J. M. (2006). Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. Journal of the American College of Cardiology, 48 (10), 2116\u20132124. https:\/\/doi.org\/10.1016\/j.jacc.2006.06.073","DOI":"10.1016\/j.jacc.2006.06.073"},{"key":"10643_CR13","doi-asserted-by":"publisher","unstructured":"Gomes, S. A., Rangel, E. B., Premer, C., Dulce, R. A., Cao, Y., Florea, V., \u2026 Hare, J. M. (2013). S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. Proceedings of the National Academy of Sciences of the United States of America, 110(8), 2834\u20132839. https:\/\/doi.org\/10.1073\/pnas.1220185110","DOI":"10.1073\/pnas.1220185110"},{"key":"10643_CR14","doi-asserted-by":"publisher","unstructured":"van Berlo, J. H., Kanisicak, O., Maillet, M., Vagnozzi, R. J., Karch, J., Lin, S.-C. J., \u2026 Molkentin, J. D. (2014). c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature, 509(7500), 337\u2013341. https:\/\/doi.org\/10.1038\/nature13309","DOI":"10.1038\/nature13309"},{"key":"10643_CR15","doi-asserted-by":"publisher","unstructured":"Kretzschmar, K., Post, Y., Bannier-H\u00e9laou\u00ebt, M., Mattiotti, A., Drost, J., Basak, O., \u2026 Clevers, H. (2018). Profiling proliferative cells and their progeny in damaged murine hearts. Proceedings of the National Academy of Sciences, 115(52), E12245\u2013E12254. https:\/\/doi.org\/10.1073\/pnas.1805829115","DOI":"10.1073\/pnas.1805829115"},{"key":"10643_CR16","doi-asserted-by":"publisher","unstructured":"Wojakowski, W., Tendera, M., Micha\u0142owska, A., Majka, M., Kucia, M., Ma\u015blankiewicz, K., \u2026 Ratajczak, M. Z. (2004). Mobilization of CD34\/CXCR4+, CD34\/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation, 110 (20), 3213\u20133220 https:\/\/doi.org\/10.1161\/01.CIR.0000147609.39780.02","DOI":"10.1161\/01.CIR.0000147609.39780.02"},{"key":"10643_CR17","doi-asserted-by":"publisher","unstructured":"Theiss, H. D., David, R., Engelmann, M. G., Barth, A., Schotten, K., Naebauer, M., \u2026 Franz, W.-M. (2007). Circulation of CD34+ progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM). European Heart Journal, 28(10), 1258\u20131264. https:\/\/doi.org\/10.1093\/eurheartj\/ehm011","DOI":"10.1093\/eurheartj\/ehm011"},{"key":"10643_CR18","doi-asserted-by":"publisher","unstructured":"Kawamoto, A., Tkebuchava, T., Yamaguchi, J.-I., Nishimura, H., Yoon, Y.-S., Milliken, C., \u2026 Asahara, T. (2003). Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation, 107(3), 461\u2013468. https:\/\/doi.org\/10.1161\/01.cir.0000046450.89986.50","DOI":"10.1161\/01.cir.0000046450.89986.50"},{"key":"10643_CR19","doi-asserted-by":"publisher","unstructured":"Iwasaki, H., Kawamoto, A., Ishikawa, M., Oyamada, A., Nakamori, S., Nishimura, H., \u2026 Asahara, T. (2006). Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation, 113(10), 1311\u20131325. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.541268","DOI":"10.1161\/CIRCULATIONAHA.105.541268"},{"key":"10643_CR20","doi-asserted-by":"crossref","unstructured":"Tendera, M., Wojakowski, W., Ruz, W., Ke, C., Nessler, J., Buszman, P., \u2026 Ratajczak, M. Z. (2009). Intracoronary infusion of bone marrow-derived selected CD341CXCR41 cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. European Heart Journal, 30, 1313\u20131321.","DOI":"10.1093\/eurheartj\/ehp073"},{"key":"10643_CR21","doi-asserted-by":"publisher","first-page":"e658480","DOI":"10.1155\/2013\/658480","volume":"2013","author":"JC Poole","year":"2013","unstructured":"Poole, J. C., & Quyyumi, A. A. (2013). Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34+ Bone Marrow Mononuclear Cells. Stem Cells International, 2013, e658480. https:\/\/doi.org\/10.1155\/2013\/658480","journal-title":"Stem Cells International"},{"key":"10643_CR22","doi-asserted-by":"publisher","unstructured":"Quyyumi, A. A., Vasquez, A., Kereiakes, D. J., Klapholz, M., Schaer, G. L., Abdel-Latif, A., \u2026 Losordo, D. W. (2017). PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI. Circulation Research, 120(2), 324\u2013331. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.308165","DOI":"10.1161\/CIRCRESAHA.115.308165"},{"key":"10643_CR23","doi-asserted-by":"publisher","unstructured":"Losordo, D. W., Henry, T. D., Davidson, C., Lee, J. S., Costa, M. A., Bass, T., \u2026 Investigatorsa, the A.-C. (2011). Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina. Circulation Research. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.245993","DOI":"10.1161\/CIRCRESAHA.111.245993"},{"key":"10643_CR24","doi-asserted-by":"publisher","unstructured":"Povsic, T. J., Henry, T. D., Traverse, J. H., Fortuin, F. D., Schaer, G. L., Kereiakes, D. J., \u2026 RENEW Investigators. (2016). The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. JACC. Cardiovascular interventions, 9(15), 1576\u20131585. https:\/\/doi.org\/10.1016\/j.jcin.2016.05.003","DOI":"10.1016\/j.jcin.2016.05.003"},{"key":"10643_CR25","doi-asserted-by":"publisher","unstructured":"Vrtovec, B., Poglajen, G., Lezaic, L., Sever, M., Socan, A., Domanovic, D., \u2026 Wu, J. C. (2013). Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation, 128(11 Suppl 1), S42\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.000230","DOI":"10.1161\/CIRCULATIONAHA.112.000230"},{"key":"10643_CR26","doi-asserted-by":"publisher","unstructured":"Quyyumi, A. A., Waller, E. K., Murrow, J., Esteves, F., Galt, J., Oshinski, J., \u2026 Pecora, A. L. (2011). CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. American Heart Journal, 161(1), 98\u2013105. https:\/\/doi.org\/10.1016\/j.ahj.2010.09.025","DOI":"10.1016\/j.ahj.2010.09.025"},{"issue":"11 Suppl 1","key":"10643_CR27","doi-asserted-by":"publisher","first-page":"II225","DOI":"10.1161\/01.CIR.0000138191.11580.e3","volume":"110","author":"K Suzuki","year":"2004","unstructured":"Suzuki, K., Murtuza, B., Fukushima, S., Smolenski, R. T., Varela-Carver, A., Coppen, S. R., & Yacoub, M. H. (2004). Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Circulation, 110(11 Suppl 1), II225-230. https:\/\/doi.org\/10.1161\/01.CIR.0000138191.11580.e3","journal-title":"Circulation"},{"issue":"3","key":"10643_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtcvs.2006.05.034","volume":"132","author":"CJ Teng","year":"2006","unstructured":"Teng, C. J., Luo, J., Chiu, R. C. J., & Shum-Tim, D. (2006). Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: Implications for cellular cardiomyoplasty. The Journal of Thoracic and Cardiovascular Surgery, 132(3), 628\u2013632. https:\/\/doi.org\/10.1016\/j.jtcvs.2006.05.034","journal-title":"The Journal of Thoracic and Cardiovascular Surgery"},{"key":"10643_CR29","doi-asserted-by":"publisher","unstructured":"M\u00fcller-Ehmsen, J., Krausgrill, B., Burst, V., Schenk, K., Neisen, U. C., Fries, J. W. U., \u2026 Schwinger, R. H. G. (2006). Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. Journal of Molecular and Cellular Cardiology, 41(5), 876\u2013884. https:\/\/doi.org\/10.1016\/j.yjmcc.2006.07.023","DOI":"10.1016\/j.yjmcc.2006.07.023"},{"issue":"3","key":"10643_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1536\/ihj.16-179","volume":"58","author":"Y Mitsutake","year":"2017","unstructured":"Mitsutake, Y., Pyun, W. B., Rouy, D., Foo, C. W. P., Stertzer, S. H., Altman, P., & Ikeno, F. (2017). Improvement of Local Cell Delivery Using Helix Transendocardial Delivery Catheter in a Porcine Heart. International Heart Journal, 58(3), 435\u2013440. https:\/\/doi.org\/10.1536\/ihj.16-179","journal-title":"International Heart Journal"},{"key":"10643_CR31","doi-asserted-by":"publisher","unstructured":"Gy\u00f6ngy\u00f6si, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., \u2026 Maurer, G. (2015). Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient Data. Circulation Research, 116(8), 1346\u20131360. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.304346","DOI":"10.1161\/CIRCRESAHA.116.304346"},{"key":"10643_CR32","doi-asserted-by":"publisher","unstructured":"Lunde, K., Solheim, S., Aakhus, S., Arnesen, H., Abdelnoor, M., Egeland, T., \u2026 Forfang, K. (2006). Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. The New England Journal of Medicine, 355(12), 1199\u20131209. https:\/\/doi.org\/10.1056\/NEJMoa055706","DOI":"10.1056\/NEJMoa055706"},{"key":"10643_CR33","doi-asserted-by":"publisher","unstructured":"Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., \u2026 Isner, J. M. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science (New York, N.Y.), 275(5302), 964\u2013967. https:\/\/doi.org\/10.1126\/science.275.5302.964","DOI":"10.1126\/science.275.5302.964"},{"key":"10643_CR34","doi-asserted-by":"publisher","unstructured":"Lagasse, E., Connors, H., Al-Dhalimy, M., Reitsma, M., Dohse, M., Osborne, L., \u2026 Grompe, M. (2000). Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nature Medicine, 6(11), 1229\u20131234. https:\/\/doi.org\/10.1038\/81326","DOI":"10.1038\/81326"},{"key":"10643_CR35","doi-asserted-by":"publisher","unstructured":"Gordon, M. Y., Levicar, N., Pai, M., Bachellier, P., Dimarakis, I., Al-Allaf, F., \u2026 Habib, N. A. (2006). Characterization and clinical application of human CD34+ stem\/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells (Dayton, Ohio), 24(7), 1822\u20131830. https:\/\/doi.org\/10.1634\/stemcells.2005-0629","DOI":"10.1634\/stemcells.2005-0629"},{"key":"10643_CR36","doi-asserted-by":"publisher","unstructured":"Matsumoto, T., Kuroda, R., Mifune, Y., Kawamoto, A., Shoji, T., Miwa, M., \u2026 Kurosaka, M. (2008). Circulating endothelial\/skeletal progenitor cells for bone regeneration and healing. Bone, 43(3), 434\u2013439. https:\/\/doi.org\/10.1016\/j.bone.2008.05.001","DOI":"10.1016\/j.bone.2008.05.001"},{"issue":"5","key":"10643_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/sj.leu.2404171","volume":"20","author":"M Kucia","year":"2006","unstructured":"Kucia, M., Reca, R., Campbell, F. R., Zuba-Surma, E., Majka, M., Ratajczak, J., & Ratajczak, M. Z. (2006). A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia, 20(5), 857\u2013869. https:\/\/doi.org\/10.1038\/sj.leu.2404171","journal-title":"Leukemia"},{"key":"10643_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7651645","volume":"2016","author":"H Sovalat","year":"2016","unstructured":"Sovalat, H., Scrofani, M., Eidenschenk, A., & H\u00e9non, P. (2016). Human Very Small Embryonic-Like Stem Cells Are Present in Normal Peripheral Blood of Young, Middle-Aged, and Aged Subjects. Stem Cells International, 2016, 1\u20138. https:\/\/doi.org\/10.1155\/2016\/7651645","journal-title":"Stem Cells International"},{"issue":"4","key":"10643_CR39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12015-018-9821-1","volume":"14","author":"R Lahlil","year":"2018","unstructured":"Lahlil, R., Scrofani, M., Barbet, R., Tancredi, C., Aries, A., & H\u00e9non, P. (2018). VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion. Stem Cell Reviews and Reports, 14(4), 510\u2013524. https:\/\/doi.org\/10.1007\/s12015-018-9821-1","journal-title":"Stem Cell Reviews and Reports"},{"issue":"2","key":"10643_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1161\/CIRCRESAHA.118.314287","volume":"124","author":"MZ Ratajczak","year":"2019","unstructured":"Ratajczak, M. Z., Ratajczak, J., & Kucia, M. (2019). Very Small Embryonic-Like Stem Cells (VSELs): An Update and Future Directions. Circulation Research, 124(2), 208\u2013210. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.314287","journal-title":"Circulation Research"},{"issue":"3","key":"10643_CR41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12015-020-09961-0","volume":"16","author":"P H\u00e9non","year":"2020","unstructured":"H\u00e9non, P. (2020). Key Success Factors for Regenerative Medicine in Acquired Heart Diseases. Stem Cell Reviews and Reports, 16(3), 441\u2013458. https:\/\/doi.org\/10.1007\/s12015-020-09961-0","journal-title":"Stem Cell Reviews and Reports"},{"key":"10643_CR42","doi-asserted-by":"publisher","unstructured":"Saucourt, C., Vogt, S., Merlin, A., Valat, C., Criquet, A., Harmand, L., \u2026 H\u00e9non, P. (2019). Design and Validation of an Automated Process for the Expansion of Peripheral Blood\u2010Derived CD34 + Cells for Clinical Use After Myocardial Infarction. STEM CELLS Translational Medicine. https:\/\/doi.org\/10.1002\/sctm.17-0277","DOI":"10.1002\/sctm.17-0277"},{"key":"10643_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-022-10373-5","author":"P H\u00e9non","year":"2022","unstructured":"H\u00e9non, P., Kowalczyk, M., Aries, A., Vignon, C., Tr\u00e9buchet, G., & Lahlil, R. (2022). Industrialized GMP Production of CD34+ Cells (ProtheraCytes\u00ae) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe. Stem Cell Reviews and Reports. https:\/\/doi.org\/10.1007\/s12015-022-10373-5","journal-title":"Stem Cell Reviews and Reports"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-023-10643-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-023-10643-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-023-10643-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T09:26:18Z","timestamp":1705742778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-023-10643-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10643"],"URL":"https:\/\/doi.org\/10.1007\/s12015-023-10643-w","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"type":"print","value":"2629-3269"},{"type":"electronic","value":"2629-3277"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"12 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave their written informed consent. The study was launched after the approval of the \u201cComit\u00e9 de Protection des Personnes (CPP) Est-4 \u2013 Strasbourg\u201d, and the authorization of the French Health Regulatory Agency (ANSM).The study was conducted according to the Guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"The pilot study was supported by a grant of the French Ministry of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Grants"}},{"value":"P.H. is staff member and stakeholder of CellProthera.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}